Ireland’s first-ever clinical study of CAR-T cell therapy for treating multiple myeloma opens

By Danielle Norton February 3, 2023 Updated February 20, 2024 4 min read

Image 2 Pictured L-R: Dr Paul Browne (Consultant Haematologist), Nicola Gardiner (Chief Medical Scientist), Dr Larry Bacon (Consultant Haematologist), Geraldine Walpole, (Chairperson of Multiple Myeloma Ireland), Dr Patrick Hayden (Consultant Haematologist)

CARTITUDE-5 provides suitable newly diagnosed patients in Ireland with a new treatment option and is now recruiting patients

Ireland’s first ever clinical trial for a cell therapy to treat multiple myeloma, a type of blood cancer, is now open at St James’s Hospital, Dublin, where eligible study participants may access a new treatment option for myeloma. CARTITUDE-5, a multicentre global study, seeks to evaluate the efficacy and safety of CAR-T as a frontline therapy in people newly diagnosed with this rare form of blood cancer for whom a stem cell transplant is not planned as an initial treatment.¹